Insulin Resistance clinical trials at UCSD
2 in progress, 1 open to eligible people
Effects of GRA in Patients With Type 1
open to eligible people ages 18-65
This study will examine the effects a Glucagon Receptor Antagonist (GRA), has on Insulin Sensitivity, Cardiovascular risks (CVD), and Ketone body formation in participants with Type 1 diabetes. The participants will complete blood tests, tests to measure energy expenditure, CVD risks, and insulin resistance. These tests will be performed prior to start of treatment and again after 12-weeks of treatment with the GRA (called REMD-477).
La Jolla, California
A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Sorry, currently not accepting new patients, but might later
Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.
San Diego, California
Our lead scientists for Insulin Resistance research studies include Mario Chojkier, M.D. Jeremy Pettus, MD.